RareMed Solutions

Overview

RareMed Solutions is a concierge patient services provider (hub services company) focused exclusively on rare disease, orphan drugs, and complex specialty therapies. The company positions itself as “the nation’s only concierge patient services provider, focused on complex and rare conditions.” Unlike many hub competitors that are vertically integrated into wholesaler, PBM, or specialty pharmacy parent organizations, RareMed operates as a fully independent entity with no supply chain affiliations — a genuine differentiator for manufacturers concerned about channel conflict.

RareMed originated as a subsidiary of PANTHERx Rare (initially called Summit Specialty Solutions, established around 2015) before completing its transition to an independent entity and rebranding as RareMed Solutions in March 2018. The founding rationale was that rare disease therapy launches demanded a dedicated hub unencumbered by the priorities of larger, multi-therapeutic-area patient services providers. Dr. Gordon Vanscoy, who also founded PANTHERx, serves as Chairman and CEO of both entities but RareMed has maintained operational independence through PANTHERx’s multiple ownership transitions (Centene acquisition in 2020, PE consortium divestiture in 2022).

The company has experienced explosive growth, achieving 359% revenue growth from 2022 to 2024 (189% CAGR), reaching approximately $76M in revenue by 2024. RareMed was named the #1 fastest-growing company on the Pittsburgh Business Times Fast 50 in 2025.

Services & Capabilities

RareMed’s service model spans the full patient access lifecycle for complex and rare disease therapies:

Patient Support / Hub Services:

• Dedicated case management via branded RareSupport Teams (therapy-specific, not shared agent pools)
• Benefits investigation and verification (BI/BV)
• Prior authorization assistance
• Reimbursement support and appeals management
• Co-pay, coupon, and financial assistance program management
• Patient adherence monitoring and education
• HCP education and nursing support

Non-Commercial Pharmacy (RareMed Direct):

• Licensed non-commercial dispensing pharmacy for free drug, bridge supply, patient assistance program (PAP) fulfillment, and emergency supply
• Overnight nationwide distribution across all 50 states
• Cold-chain and specialty logistics leveraging proximity to international air cargo facilities (Pittsburgh and Orlando)

Hub Deployment Models:

• Fully outsourced (external) hubs
• Hybrid hubs (co-managed with manufacturer internal teams)
• Fully insourced hubs (manufacturer runs internal hub on RareMed’s technology platform)
• RareMed claims to be the only provider supporting all three models

Specialty Pharmacy Network Coordination: RareMed does not design or select LDD networks — that function sits with distribution strategy consultants like Archbow Consulting or Blue Fin Group. Instead, RareMed coordinates across whatever SP network the manufacturer has established: managing prescription routing, patient case status, data aggregation from network pharmacies, and communication between hub and dispensing pharmacies. In one documented hub transition, RareMed achieved a 76% reduction in prescription transfers, eliminated 12% of duplicate patient records, and delivered >15% increase in enrollment conversion rates.

Competitive Position

RareMed competes in the specialty patient services / hub services market against significantly larger, vertically integrated competitors. Key competitors include Cencora/Lash Group (legacy leader, 30+ years, but channel conflict via parent distributor/SP ownership), CareMetx (digital-first platform, General Atlantic/Vistria-backed), AssistRx (tech + talent model, WCAS-backed), Eversana (full commercialization suite), ConnectiveRx (copay/coupon + hub), and McKesson Patient Support (wholesaler-backed).

RareMed’s competitive differentiation rests on three pillars:

1. Rare disease specialization: Unlike large hub providers that serve thousands of brands across all therapeutic areas, RareMed maintains deliberate concentration on rare, orphan, and complex conditions. This enables dedicated, therapy-specific teams rather than shared agent pools.

2. Supply chain independence: No parent wholesaler, PBM, or specialty pharmacy. This contrasts sharply with Lash Group (Cencora), UBC (Cigna/Express Scripts), and McKesson/Cardinal hub arms. For manufacturers with mixed SP networks containing both PBM-owned and independent pharmacies, a neutral hub removes concerns about steering.

3. Concierge service quality: RareMed achieved a perfect Net Promoter Score of 100 on MMIT’s nationwide Patient Satisfaction Survey (Q1 2025) and won the MMIT Patient Choice Award for 2025 (highest three-year average patient satisfaction scores).

At ~$76M revenue, RareMed is still modest in scale relative to competitors backed by Cencora ($260B parent), General Atlantic, or McKesson. Independence also means it lacks the distribution infrastructure, payer leverage, and pharmacy network depth of vertically integrated rivals.

Recent Developments

• March 2026: Expansion to Orlando, Florida (fourth office location), chosen for air cargo access and specialty pharmacy talent pool. Also announced RarePath as a standalone licensable product.
• November 2025: Named #1 overall on Pittsburgh Business Times Fast 50 (fastest-growing company in the region). Revenue reported at ~$76M for 2024 with 359% two-year growth.
• September 2025: Expanded partnership with PTC Therapeutics for Sephience (sepiapterin) NCP dispensing for PKU.
• June 2025: Achieved perfect NPS of 100 on MMIT Patient Satisfaction Survey; received MMIT Patient Choice Award 2025.
• 2024: Pittsburgh Fast 50 #9; launched “largest program to date”; described as “largest growth period ever.”
• June 2023: Opened new Pittsburgh headquarters at 200 Industry Drive (140% footprint expansion from prior facility).
• May 2023: Drug Channels covered RareMed’s expansion from rare-only to rare + complex prevalent conditions.
• March 2018: Completed transition from PANTHERx subsidiary (Summit Specialty Solutions) to independent entity, rebranded as RareMed Solutions.

No M&A activity involving RareMed as acquirer or target has been publicly reported. The notable related transaction is the PE consortium’s (Vistria/General Atlantic/Nautic) $2.8B combined acquisition of PANTHERx from Centene in 2022, which did not appear to include RareMed.

Client & Partner Ecosystem

RareMed does not publicly disclose its full client roster. Known relationships include:

• PTC Therapeutics — expanded relationship announced September 2025 for Sephience (sepiapterin) NCP dispensing for PKU
• PANTHERx Rare — sister entity (shared founder/CEO Dr. Gordon Vanscoy); PANTHERx handles commercial specialty dispensing for rare disease while RareMed provides the hub/NCP layer
• Vanscoy Rare — newer rare disease pharmacy venture also led by Dr. Vanscoy, positioning as an independent alternative to PANTHERx’s PE-backed model

Revenue of ~$76M with 359% growth over two years implies the company likely serves 5-15+ biopharma manufacturer programs, depending on program size and fee structure. The 2024 “largest program to date” language suggests at least one major rare disease launch anchor client.

Technology Platform

RarePath — proprietary patient care management software suite built entirely in-house by a full-stack engineering team:

• AI-integrated features (predictive workflows, personalized care journeys)
• Real-time dashboards (RarePath Insights)
• Manufacturer, HCP, and patient portals
• Customizable program workflows, status definitions, KPIs, and business rules
• Scalable from patient populations in the hundreds to millions
• Territory management, bidirectional messaging, pharmacy network data integration
• Adverse event and product complaint reporting
• Recently launched as a standalone licensable product for manufacturers running insourced hubs

RareMed won the Pittsburgh Technology Council’s Innovator of the Year award for RarePath. The platform’s licensable model is a strategic expansion — it allows RareMed to generate revenue from manufacturers who want to run their own internal hubs rather than outsourcing to RareMed’s staff.

Therapeutic Focus

• Rare and orphan diseases — core origin and primary focus; inherited deep DNA from PANTHERx Rare’s founding team
• Complex prevalent conditions — expansion beginning ~2023 to address larger patient populations with complex access needs
• Specialty oncology — specifically rare oncology
• Precision medicine and gene therapies — emerging area as pipeline of cell and gene therapies creates demand for hub services
• Cold-chain therapies — logistics infrastructure (including RareMed Direct NCP) supports temperature-sensitive products

The broader market context for RareMed’s positioning: as of January 2025, there were 382 unique limited distribution drugs tracked in MMIT’s Access database. Every new rare disease, gene therapy, or complex specialty launch creates incremental demand for hub services. See REMS & Limited Distribution and specialty drug commercialization for market dynamics.

ZoomInfo) to 355 (Growjo). RareMed’s own materials reference “over a thousand dedicated RareMed associates,” suggesting program-dedicated contract/embedded staff may push total headcount well above core FTEs. This variability is common for hub companies where staff scale with program wins.

• Data gaps: Specific NCP pharmacy accreditations (ACHC, URAC, etc.) not confirmed for RareMed Direct (sister entity PANTHERx holds quadruple accreditation). Full client list remains undisclosed. No public financial statements beyond Pittsburgh Business Times reporting.
• Related concepts: REMS & Limited Distribution, Patient Access Journey, PE Consolidation in Pharma Services